secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-10-06T20:22:54+00:00
Accession:  0001048477-26-000019
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02
LLM model:  deepseek-v4.1-flash:cloud@v2

BioMarin sees ~$283M Q3 IPR&D charge from Alesta deal, $1.50 hit to GAAP and non-GAAP EPS
--------------------------------------------------------------------------------

- BioMarin expects ~$283M of pre-tax acquired IPR&D expense in Q3 2026 tied to the Alesta Therapeutics B.V. acquisition, completed August 31, 2026.
- The Q3 charge plus ongoing operating expenses cut about $1.50 from both GAAP diluted EPS and Non-GAAP Diluted EPS for the third quarter of 2026.
- Full-year 2026 pre-tax charges expected at ~$320M, including transaction and transition costs, an unfavorable ~$1.55 impact to both GAAP and Non-GAAP Diluted EPS.
- BioMarin's previously announced August 6, 2026 full-year 2026 guidance did not reflect Alesta; updated FY2026 guidance will come with Q3 2026 results.
- Results for the quarter ended September 30, 2026 are not finalized and remain subject to BioMarin's financial statement closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847726000019/0001048477-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847726000019/bmrn-20261006.htm
  HTML page:      https://secwatch.observer/filing/0001048477-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer